-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $50

Benzinga·10/21/2026 18:54:05
语音播报
Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $45 to $50.